Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
    • 26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 06 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Mar 2016 as reported by clinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top